Back to Search
Start Over
Mid-treatment 18F-FDG PET imaging changes in parotid gland correlates to radiation-induced xerostomia.
- Source :
-
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology [Radiother Oncol] 2023 Sep; Vol. 186, pp. 109745. Date of Electronic Publication: 2023 Jun 15. - Publication Year :
- 2023
-
Abstract
- Background: The aim of this study was to measure functional changes in parotid glands using mid-treatment FDG-PET/CT and correlate early imaging changes to subsequent xerostomia in mucosal head and neck squamous cell carcinoma patients undergoing radiotherapy.<br />Materials and Methods: 56 patients from two prospective imaging biomarker studies underwent FDG-PET/CT at baseline and during radiotherapy (week 3). Both parotid glands were volumetrically delineated at each time point. PET parameter SUV <subscript>median</subscript> were calculated for ipsilateral and contralateral parotid glands. Absolute and relative change (Δ) in SUV <subscript>median</subscript> were correlated to moderate-severe xerostomia (CTCAE grade ≥ 2) at 6 months. Four predictive models were subsequently created using multivariate logistic regression using clinical and radiotherapy planning parameters. Model performance was calculated using ROC analysis and compared using Akaike information criterion (AIC) RESULTS: 29 patients (51.8%) developed grade ≥ 2 xerostomia. Compared to baseline, there was an increase in SUV <subscript>median</subscript> at week 3 in ipsilateral (8.4%) and contralateral (5.5%) parotid glands. Increase in ipsilateral parotid Δ SUV <subscript>median</subscript> (p = 0.04) and contralateral mean parotid dose (p = 0.04) were correlated to xerostomia. The reference 'clinical' model correlated to xerostomia (AUC 0.667, AIC 70.9). Addition of ipsilateral parotid Δ SUV <subscript>median</subscript> to the clinical model resulted in the highest correlation to xerostomia (AUC 0.777, AIC 65.4).<br />Conclusion: Our study shows functional changes occurring in the parotid gland early during radiotherapy. We demonstrate that integration of baseline and mid-treatment FDG-PET/CT changes in the parotid gland with clinical factors has the potential to improve xerostomia risk prediction which could be utilised for personalised head and neck radiotherapy.<br />Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [All authors have completed the ICMJE uniform disclosure form. MJ received payments for lecture from Elektra AB. MJ and PK have funding from NSW cancer grants. PC receives funding from South-Western Sydney local health district. The other authors have no conflicts of interest to declare.].<br /> (Crown Copyright © 2023. Published by Elsevier B.V. All rights reserved.)
- Subjects :
- Humans
Fluorodeoxyglucose F18
Radiotherapy Dosage
Parotid Gland diagnostic imaging
Parotid Gland pathology
Prospective Studies
Positron Emission Tomography Computed Tomography
Positron-Emission Tomography
Head and Neck Neoplasms diagnostic imaging
Head and Neck Neoplasms radiotherapy
Head and Neck Neoplasms pathology
Xerostomia diagnostic imaging
Xerostomia etiology
Xerostomia pathology
Radiation Injuries pathology
Subjects
Details
- Language :
- English
- ISSN :
- 1879-0887
- Volume :
- 186
- Database :
- MEDLINE
- Journal :
- Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 37330056
- Full Text :
- https://doi.org/10.1016/j.radonc.2023.109745